SOPHiA GENETICS raises USD 57.5 million in oversubscribed public offering

SOPHiA GENETICS, the Lausanne-based leader in AI-driven precision medicine, has closed an oversubscribed public offering with gross proceeds of USD 57.5 million to expand its platform, applications and partnerships.

SOPHiA GENETICS, a Lausanne-based healthcare technology company specializing in AI-driven precision medicine, has closed an oversubscribed public offering with total gross proceeds of USD 57.5 million. The company sold 12,104,900 ordinary shares at USD 4.75 each, with underwriters fully exercising their option to purchase additional shares amid strong investor demand.

The proceeds are earmarked for the expansion of the company’s platform, the development of new applications, entry into new geographies, and new partnerships. The raise follows a period of momentum, including a recently formed joint venture with the cancer center Memorial Sloan Kettering and a leadership transition that sees Ross Muken move up to chief executive officer.

A cloud-native company, SOPHiA GENETICS is the creator of SOPHiA DDM, a platform that analyzes complex genomic and multimodal data to generate real-time, actionable insights for hospitals, laboratories and biopharmaceutical institutions. The platform is used by close to 1,000 healthcare institutions worldwide, helping expand access to data-driven care for patients with cancer and rare disorders.

In the first quarter of 2026, the company reported revenue of USD 21.7 million, up 22 percent year over year. SOPHiA GENETICS expects to approach adjusted EBITDA breakeven by the end of 2026 and to turn adjusted EBITDA positive in the second half of 2027. Founded in the Lake Geneva region’s “Health Valley” and active internationally, the company is among the most established names in Western Switzerland’s healthtech ecosystem.